All In Biotech

NDA 020465 · Pharmacia and Upjohn

Azulfidine

Sulfasalazine · Oral

Last checked: Nov 20, 2026Latest source record: Oct 17, 1996 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Oct 17, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

104

33 Phase 3, 14 recruiting

FAERS reports

77,206

64,651 serious, 7,369 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 17, 1996 Original approval · Type 6 - New Indication (no longer used) LetterLabel
1 products under this application
  • AZULFIDINE · SULFASALAZINE 500MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sulfasalazine" as an intervention, any sponsor and status, largest first.

All 104 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective29,465
  • rheumatoid arthritis19,619
  • pain16,065
  • drug intolerance13,852
  • arthralgia13,559
  • fatigue13,435
  • joint swelling12,834
  • off label use11,241
  • rash11,080
  • abdominal discomfort10,165
  • contraindicated product administered9,780
  • condition aggravated9,676

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004617
2005576
2006640
2007694
2008721
2009788
2010865
20111,144
20121,439
20131,320
20141,450
20152,286
20163,208
20175,103
20186,182
20197,297
202011,184
20217,160
20227,093
20235,095
20245,714
20254,546
20262,083

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azulfidine (Sulfasalazine)

2024 spending

$232K

Beneficiaries

171

532 claims

Per beneficiary

$1,358

$1.73 per unit

View as table
YearSpending
2020$387,390
2021$579,871
2022$433,431
2023$272,281
2024$232,222

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 569 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.